11/14/22 8:00 AMNasdaq : PRLD earningsPrelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business UpdateFDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0RHEA-AIneutral
10/18/22 8:00 AMNasdaq : PRLD Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein DegraderPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and DrugRHEA-AIneutral
09/06/22 8:00 AMNasdaq : PRLD conferencesPrelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare ConferencesPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. On Monday,RHEA-AIneutral
08/09/22 8:00 AMNasdaq : PRLD earningsPrelude Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdatePrelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the second half of 2022RHEA-AIneutral
05/10/22 8:00 AMNasdaq : PRLD earningsPrelude Therapeutics Announces First Quarter 2022 Financial Results and Operations UpdatePrelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022RHEA-AIpositive
03/16/22 7:30 AMNasdaq : PRLD earningsPrelude Therapeutics Reports Full Year 2021 Financial ResultsSignificant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds andRHEA-AIpositive
03/11/22 8:00 AMNasdaq : PRLD conferencesPrelude Therapeutics to Participate at the Barclays 2022 Global Healthcare ConferencePrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference inRHEA-AIneutral
03/09/22 8:05 AMNasdaq : PRLD clinical trialPrelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual MeetingAnnounces strategic prioritization within lead programs targeting PRMT5 and MCL1 Describes new pipeline candidate, PRT3645, a highly brain penetrant CDK4/6 inhibitor; IND submission planned mid-2022 Advances PRT2527, a highly selective CDK9 inhibitor, with the goal of establishing a recommendedRHEA-AIpositive
03/09/22 8:00 AMNasdaq : PRLD Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical OfficerPrelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4,RHEA-AIvery positive
02/11/22 7:00 AMNasdaq : PRLD conferencesPrelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferencePrelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday,RHEA-AIneutral